Rockwood N. Efficient likelihood estimation of generalized structural equation models with a mix of normal and nonnormal responses. Psychometrika. 2021 Jun;86(2):642-67. doi: 10.1007/s11336-021-09770
Rockwood NJ. Maximum likelihood estimation of multilevel structural equation models with random slopes for latent covariates. Psychometrika. 2020 Jun;85(2):275-300. doi: 10.1007/s11336-020-09702-9
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Cainzos-Achirica M, Bilal U, Al Rifai M, McEvoy JW, Blumenthal RS, Kapoor K, Martinez-Sanchez JM, Comin-Colet J, Pladevall-Vila M, Blaha MJ. Communication issues in nutritional observational research. Prev Med. 2018 Oct;115:76-82. doi: 10.1016/j.ypmed.2018.08.024
Mueller N, Rojas-Rueda D, Salmon M, Martinez D, Ambros A, Brand C, De Nazelle A, Dons E, Gaupp-Berghausen M, Gerike R, Gotschi T, Iacorossi F, Panis LI, Kahlmeier S, Raser E, Nieuwenhuijsen M, PASTA consortium. Health impact assessment of cycling network expansions in European cities. Prev Med. 2018 Apr;109:62-70. doi: 10.1016/j.ypmed.2017.12.011
Karanth SS, Lairson DR, Huang D, Savas LS, Vernon SW, Fernandez ME. The cost of implementing two small media interventions to promote HPV vaccination. Prev Med. 2017 Jun;99:277-81. doi: 10.1016/j.ypmed.2017.03.002
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med. 2011 Jan;52(1):10-5. doi: 10.1016/j.ypmed.2010.09.016
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Hahn EJ, Rayens MK, Chirila C, Riker CA, Paul TP, Warnick TA. Effectiveness of a quit and win contest with a low-income population. Prev Med. 2004 Sep 1;39(3):543-50.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000 Apr 1;30(4):328-38.
Yung YF, Thissen D, McLeod LD. On the relationship between the higher-order factor model and the hierarchical factor model. Psychometrika. 1999 Jun;64:113-28.
Rothman KJ. The proportion of cancer attributable to alcohol-consumption. Prev Med. 1980 Mar 1;9(2):174-9.